Brokers Offer Predictions for TARS FY2030 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at HC Wainwright issued their FY2030 EPS estimates for Tarsus Pharmaceuticals in a note issued to investors on Tuesday, February 24th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of $6.36 for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The firm had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million.

A number of other research analysts have also commented on TARS. Zacks Research upgraded Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Guggenheim raised their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $72.65 on Wednesday. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $85.25. The company has a market cap of $3.09 billion, a P/E ratio of -44.85, a P/E/G ratio of 1.08 and a beta of 0.57. The business’s 50 day moving average is $72.15 and its two-hundred day moving average is $68.38. The company has a quick ratio of 4.25, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by insiders.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Tarsus Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after buying an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after purchasing an additional 1,394 shares during the period. Jane Street Group LLC raised its holdings in Tarsus Pharmaceuticals by 105.8% during the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock worth $537,000 after purchasing an additional 190,000 shares during the last quarter. Allianz Asset Management GmbH acquired a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $227,000. Finally, Envestnet Asset Management Inc. lifted its position in Tarsus Pharmaceuticals by 15.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock valued at $420,000 after purchasing an additional 1,418 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Analyst price-target upgrade — Oppenheimer raised its target to $105 and kept an “outperform” rating, implying substantial upside versus current levels. Oppenheimer Raises TARS Target to $105
• Positive Sentiment: Analyst price-target increase — Guggenheim nudged its target to $90 and reiterated a “buy” rating, signaling continued analyst confidence after the quarter. Guggenheim Raises TARS Target to $90
• Positive Sentiment: Very bullish long-term EPS forecast — HC Wainwright published a FY2030 estimate of $6.36 per share (vs. street FY2026 EPS expectations that are negative), reflecting high conviction in XDEMVY’s multi-year growth potential. HC Wainwright FY2030 EPS Estimate
• Positive Sentiment: Strong Q4 results and guidance — Management reported FY2025 revenue up ~150% to $451M, gave 2026 guidance of $670–$700M, highlighted ~93% gross margins and reiterated XDEMVY’s >$2B peak-sales potential with international launches planned. These items support upside and explain the analyst optimism. Tarsus Expects $670M–$700M 2026 Sales
• Neutral Sentiment: Earnings call materials available — Transcripts and the investor presentation were published for review; they provide detail on commercialization cadence and international timing but contain no new surprise announcements. Earnings Call Transcript
• Neutral Sentiment: Investor write-ups and summaries posted — Multiple outlets summarized the quarter and guidance; useful for modeling but not market-moving by themselves. Q4 Earnings Call Summary
• Negative Sentiment: Slight EPS miss and reported quarterly loss — Tarsus posted a loss of $0.20 vs. a consensus loss of $0.19 (a small miss), which, despite the revenue beat, likely contributed to selling pressure and the intraday decline. Q4 Loss, Beats Revenue Estimates

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.